drugset
drugset / Trial / NCT06644404

Phase 1 Study of Drug-Drug Interactions Between DWP16001, DWC202407, and DWC202408 in Healthy Adults

NCT06644404 ↗

Phase 1 Not yet recruiting 34 enrolled Daewoong Pharmaceutical Co. LTD.
RandomizedCrossoverOpen-labelTreatment

Summary

This study aims to evaluate the pharmacokinetic/pharmacodynamic drug-drug interactions between DWP16001, DWC202407, and DWC202408 in healthy adults

Timeline

Start
2024-10-26
Primary completion
2024-12-03
Completion
2025-04-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Enavogliflozin Small molecule 0.3 mg Oral
Subject Glimepiride Small molecule 2 mg Oral
Subject Metformin Small molecule 1000 mg Oral

Indications

No indication recorded.